- Home
- WIA vs MDWD Comparison
WIA vs MDWD Comparison
Compare WIA & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WIA
- MDWD
- Stock Information
- Founded
- WIA 2003
- MDWD 2000
- Country
- WIA United States
- MDWD Israel
- Employees
- WIA N/A
- MDWD N/A
- Industry
- WIA Trusts Except Educational Religious and Charitable
- MDWD Medicinal Chemicals and Botanical Products
- Sector
- WIA Finance
- MDWD Health Care
- Exchange
- WIA Nasdaq
- MDWD Nasdaq
- Market Cap
- WIA 186.8M
- MDWD 184.8M
- IPO Year
- WIA N/A
- MDWD 2014
- Fundamental
- Price
- WIA $8.22
- MDWD $19.45
- Analyst Decision
- WIA
- MDWD Strong Buy
- Analyst Count
- WIA 0
- MDWD 1
- Target Price
- WIA N/A
- MDWD $25.00
- AVG Volume (30 Days)
- WIA 39.2K
- MDWD 78.0K
- Earning Date
- WIA 01-01-0001
- MDWD 03-20-2025
- Dividend Yield
- WIA 12.29%
- MDWD N/A
- EPS Growth
- WIA N/A
- MDWD N/A
- EPS
- WIA N/A
- MDWD N/A
- Revenue
- WIA N/A
- MDWD $19,720,000.00
- Revenue This Year
- WIA N/A
- MDWD $10.15
- Revenue Next Year
- WIA N/A
- MDWD $25.62
- P/E Ratio
- WIA N/A
- MDWD N/A
- Revenue Growth
- WIA N/A
- MDWD N/A
- 52 Week Low
- WIA $7.56
- MDWD $11.04
- 52 Week High
- WIA $8.91
- MDWD $24.00
- Technical
- Relative Strength Index (RSI)
- WIA 59.46
- MDWD 55.03
- Support Level
- WIA $8.09
- MDWD $19.59
- Resistance Level
- WIA $8.21
- MDWD $20.62
- Average True Range (ATR)
- WIA 0.09
- MDWD 0.83
- MACD
- WIA 0.02
- MDWD 0.02
- Stochastic Oscillator
- WIA 73.33
- MDWD 54.60
About WIA Western Asset Inflation-Linked Income Fund
Western Asset Inflation Linked Income Fund is a diversified, closed-end management investment company. The primary investment objective of the group is to provide current income while its secondary investment objective is capital appreciation.
About MDWD MediWound Ltd.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.